Mygn stock price charts show a bullish crossover in the

MYGN stock price charts show a bullish crossover in the 20-day moving average, aligning with positive sentiment in diagnostics and genetic research equities. Traders are setting alerts for volume spikes above $17. Myriad Genetics exited the first quarter of 2025 with an earnings beat and a revenue miss. The top line also decreased on a year-over-year basis. In the Pharmacogenomics business, GeneSight revenues were impacted by UnitedHealthcare’s coverage policy change effective Jan. 1, as well as the company’s marketing spend reallocation actions. Hereditary business in the women's health channel continued to be impacted by electronic medical record (EMR) integrations ramping up slower than expected. Myriad Genetics lowered its financial guidance for the full year, as current initiatives to re-accelerate testing volumes will take time. Additionally, the contraction of the gross margin was discouraging. Myriad Genetics’s five-year average ROIC was negative 31.8%, meaning management lost money while trying to expand the business. Its returns were among the worst in the healthcare sector. MYGN stock price is trading just below a key resistance zone, and momentum indicators such as RSI are highlighting neutral conditions, leaving space for both upward and downward moves depending on news flow.